Documents

Current Vision of Rhinosinusitis and Recent Progress in Advanced Sinonasal Endoscopic Surgery


Current Vision of Rhinosinusitis
and recent progress in advanced sinonasal endoscopic surgery
Medical forum. Valencia, March 2007
Keywords of Current Vision of Rhinosinusitis 2007 - PDF


OVERVIEW

Between 5 and 10% of the Spanish population may suffer some type or degree of rhinosinusitis, a disease whose prevalence is increasing worldwide and which has a growing impact both on the patient’s quality of life and on socioeconomic parameters. However, there is still room for hope.
The recent creation of a European consensus on the diagnosis and treatment of rhinosinusitis and nasal polyposis, and the accumulation of evidence with new treatment resources have not only enabled the problem to be identified and delimited but effective and innovative therapies (such as those based on the administration of plant extract-based preparations) have also made available to patients.

With the goal of reviewing this progress, offering an up-to-date vision of rhinosinusitis and outlining the significant successes that are being achieved in advanced sinonasal endoscopic surgery, a Medical Forum sponsored by Laboratorios Zambon was held on 10 March this year at Valencia.

The meeting, attended by almost 200 Spanish experts, was divided into two sessions. Dr. Ramona Soler, from the Hospital Son Dureta in Palma of Mallorca, was the moderator of the table that discussed the current vision of rhinosinusitis, with contributions from Drs. Isam Alobid, Joan Montserrat and Primitivo Ortega. Dr. Adolfo Sarandeses, from the Hospital Juan Canalejo in La Corunna, coordinated the table that reviewed some of the recent progress in advanced sinonasal endoscopic surgery. In this case, the lead speakers were Drs. Ernesto Pasquini and Humbert Massegur.

Particular attention was paid at this meeting to Nasodren®, a plant-based preparation that does not contain hormones or preservatives and only acts locally, without irritating the mucous membranes of the nose and paranasal sinuses. These parameters make it a safe, fast-acting adjuvant in inflammatory conditions of the nose and paranasal sinuses (and also in postoperative care).

The cyclamen europaeum L. tuber extract used in Nasodren® contains a number of substances, including cyclamen. After intranasal administration, it triggers a response on the mucous surface, stimulating the trigeminal nerve fibres to trigger an intense reflex secretory response, with almost immediate dehydration and retraction of the mucosa and opening of the inflamed osteomeatal complex. The secretion causes an intense physiological drainage of the paranasal sinuses.



Current Vision of Rhinosinusitis - Index

EP3OS Guideline. Consensus in the management of rhinosinusitis... - Next Article

Hartington Pharma owns Nasodren® for sinusitis treatment